Claims:

1. A composition comprising gabapentin and at most 5 ppm, based on the amount of the gabapentin, of an addition salt of gabapentin and an acid.

2. The composition of Claim 1, comprising at most 4 ppm of the addition salt of gabapentin and an acid.

3. The composition of Claim 1, comprising at most 3 ppm of the addition salt of gabapentin and an acid.

4. The composition of Claim 1, comprising at most 2 ppm of the addition salt of gabapentin and an acid.

5. The composition of Claim 1, comprising at most 1 ppm of the addition salt of gabapentin and an acid.

6. The composition of Claim 1, comprising at most 0.5 ppm of the addition salt of gabapentin and an acid.

7. The composition of Claim 1, comprising at most 0.25 ppm of the addition salt of gabapentin and an acid.

8. The composition of Claim 1, comprising at most 0.1 ppm of the addition salt of gabapentin and an acid.

9. The composition of Claim 1, comprising at most 0.05 ppm of the addition salt of gabapentin and an acid.

10. The composition of Claim 1, comprising no detectable quantity of the addition salt of gabapentin and an acid.

11. The composition of Claim 9, which contains no detectable quantity of the addition salt of gabapentin by silver nitrate titration.

12. The composition of Claim 1, wherein the acid is a mineral acid.

13. The composition of Claim 1, wherein the mineral acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, nitric acid, sulfuric acid, sulfonic acid, methanesulfonic acid.

14. The composition of Claim 1, wherein the mineral acid is hydrochloric acid.

15. The composition of Claim 1, which comprises at most 0.5% by weight of gabapentin lactam.

16. The composition of Claim 1, which comprises at most 1% by weight of water.

17. The composition of Claim 1, which comprises at most 0.5% by weight of gabapentin lactam and at most 1% by weight of water.

18. A pharmaceutical composition in dry unit dosage form, comprising:

(a) gabapentin;

(b) at most 5 ppm, based on the amount of the gabapentin, of an addition salt of gabapentin and an acid; and

(c) at least one nonacidic pharmaceutically acceptable excipient.

19. A composition, comprising gabapentin and at least one salt of a nonacidic cation and an anion of a mineral acid, wherein the composition comprises more than 20 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

20. The composition of Claim 19, which contains more than 25 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

21. The composition of Claim 19, which contains more than 30 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

22. The composition of Claim 19, which contains more than 50 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

23. The composition of Claim 19, which contains more than 75 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

24. The composition of Claim 19, which contains more than 100 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

25. The composition of Claim 19, which contains more than 250 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

26. The composition of Claim 19, which contains more than 500 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

27. The composition of Claim 19, which contains more than 1000 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

28. The composition of Claim 19, which contains more than 2000 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

29. The composition of Claim 19, comprising at most 5 ppm of one or more addition salts of gabapentin and an acid.

30. The composition of Claim 19, wherein the nonacidic cation is selected from the group consisting of alkali metals and alkaline earth metals.

31. The composition of Claim 30, wherein the nonacidic cation is selected from the group consisting of lithium, sodium, potassium, magnesium, and calcium.

32. The composition of Claim 19, wherein the nonacidic cation is selected from the group consisting of quaternary ammonium groups.

33. The composition of Claim 32, wherein the quaternary ammonium groups are selected from the group consisting of tetraalkyl ammonium groups.

34. The composition of Claim 19, wherein the anion an acid is selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, and phosphate.

35. The composition of Claim 19, wherein the anion of a mineral acid is chloride.

36. The composition of Claim 19, wherein the salt is sodium chloride.

37. A pharmaceutical composition in dry unit dosage form, comprising:

(a) gabapentin;

(b) at least one salt of a nonacidic cation and an anion of a mineral acid, and

(c) at least one nonacidic excipient

wherein the composition contains at least 20 ppm of the anion of a mineral acid, based on the amount of the gabapentin.

38. A method of treating a cerebral disease, comprising administering an effective amount of the composition of Claim 1 to a subject in need thereof.

39. The method of Claim 38, wherein the cerebral disease is epilepsy, faintness attacks, hypokinesia, dizziness, or cranial trauma.

40. A method of improving cerebral function, comprising administering an effective amount of the composition of Claim 1 to a subject in need thereof.

41. The method of Claim 40, wherein the subject is a geriatric patient.

42. A method of treating a neurodegenerative disorder, perinatal, comprising administering an effective amount of the composition of Claim 1 to a subject in need thereof.

43. The method of Claim 42, wherein the neurodegenerative disorder is stroke, Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, or Parkinson's disease.

44. A method of treating depression, comprising administering an effective amount of the composition of Claim 1 to a subject in need thereof.

45. A method of treating anxiety, comprising administering an effective amount of the composition of Claim 1 to a subject in need thereof.

46. A method of treating or preventing panic attacks, comprising administering an effective amount of the composition of Claim 1 to a subject in need thereof.

47. A method of treating a cerebral disease, comprising administering an effective amount of the composition of Claim 18 to a subject in need thereof.

48. The method of Claim 47, wherein the cerebral disease is epilepsy, faintness attacks, hypokinesia, dizziness, or cranial trauma.

49. A method of improving cerebral function, comprising administering an effective amount of the composition of Claim 18 to a subject in need thereof.

50. The method of Claim 49, wherein the subject is a geriatric patient.

51. A method of treating a neurodegenerative disorder, perinatal, comprising administering an effective amount of the composition of Claim 18 to a subject in need thereof.

52. The method of Claim 51, wherein the neurodegenerative disorder is stroke, Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, or Parkinson's disease.

53. A method of treating depression, comprising administering an effective amount of the composition of Claim 18 to a subject in need thereof.

54. A method of treating anxiety, comprising administering an effective amount of the composition of Claim 18 to a subject in need thereof.

55. A method of treating or preventing panic attacks, comprising administering an effective amount of the composition of Claim 18 to a subject in need thereof.

56. A method of treating a cerebral disease, comprising administering an effective amount of the composition of Claim 19 to a subject in need thereof.

57. The method of Claim 56, wherein the cerebral disease is epilepsy, faintness attacks, hypokinesia, dizziness, or cranial trauma.

58. A method of improving cerebral function, comprising administering an effective amount of the composition of Claim 19 to a subject in need thereof.

59. The method of Claim 58, wherein the subject is a geriatric patient.

60. A method of treating a neurodegenerative disorder, perinatal, comprising administering an effective amount of the composition of Claim 19 to a subject in need thereof.

61. The method of Claim 60, wherein the neurodegenerative disorder is stroke, Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, or Parkinson's disease.

62. A method of treating depression, comprising administering an effective amount of the composition of Claim 19 to a subject in need thereof.

63. A method of treating anxiety, comprising administering an effective amount of the composition of Claim 19 to a subject in need thereof.

64. A method of treating or preventing panic attacks, comprising administering an effective amount of the composition of Claim 19 to a subject in need thereof.

65. A method of treating a cerebral disease, comprising administering an effective amount of the composition of Claim 37 to a subject in need thereof.

66. The method of Claim 65, wherein the cerebral disease is epilepsy, faintness attacks, hypokinesia, dizziness, or cranial trauma.

67. A method of improving cerebral function, comprising administering an effective amount of the composition of Claim 37 to a subject in need thereof.

68. The method of Claim 67, wherein the subject is a geriatric patient.

69. A method of treating a neurodegenerative disorder, perinatal, comprising administering an effective amount of the composition of Claim 37 to a subject in need thereof.

70. The method of Claim 69, wherein the neurodegenerative disorder is stroke, Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, or Parkinson's disease.

71. A method of treating depression, comprising administering an effective amount of the composition of Claim 37 to a subject in need thereof.

72. A method of treating anxiety, comprising administering an effective amount of the composition of Claim 37 to a subject in need thereof.

73. A method of treating or preventing panic attacks, comprising administering an effective amount of the composition of Claim 37 to a subject in need thereof.